| Item |
Information |
|
Drug Groups
|
withdrawn |
|
Description
|
On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal Rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Canadian market. |
| Indication |
Used as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Types IIa and IIb) when the response to dietary restriction of saturated fat and cholesterol and other non-pharmacological measures alone has been inadequate. |
| Pharmacology |
Cerivastatin, a competitive HMG-CoA reductase inhibitor effective in lowering LDL cholesterol and triglycerides, is used to treat primary hypercholesterolemia and mixed dyslipidemia (Fredrickson types IIa and IIb). |
| Toxicity |
Rhabdomyolysis, liver concerns |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
Hepatic. Biotransformation pathways for cerivastatin in humans include the following: demethylation of the benzylic methyl ether to form Ml and hydroxylation of the methyl group in the 6'-isopropyl moiety to form M23. |
| Absorption |
The mean absolute oral bioavailability 60% (range 39 - 101%). |
| Half Life |
2-3 hours |
| Protein Binding |
More than 99% of the circulating drug is bound to plasma proteins (80% to albumin). |
| References |
| • |
Furberg CD, Pitt B: Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med. 2001;2(5):205-207.
[Pubmed]
|
|
| External Links |
|